Citations

Clear

2 citation(s) found for "Zhou, Fang".

Peptide-Guided Nanoparticle Drug Delivery for Cardiomyocytes
Taylor, Austin L., Shi, Haiwang , Zhou, Fang , Li, Pengsheng , Joshi, Jyotsna, Zhu, Wuqiang , Wang, Shu , Zhou, Fang , Zhu, Wuqiang , Wang, Shu , Li, Dong , Taylor, Austin

Mayo Clinic

Biology | January 16, 2024 | Volume: 13 | Issue: 1 | Pages: 47

10.3390/biology13010047 | PMID 38248477 Get It

Background: Nanoparticles (NPs) have been extensively utilized as a drug delivery system to control the release of therapeutic agents to treat cardiac injuries. However, despite the advantages of utilizing NP-based drug delivery for treating heart diseases, the current delivery system lacks specificity in targeting the cardiac tissue, thus limiting its application. Methods: We created three linear peptides, each consisting of 16–24 amino acids. These peptides were conjugated on the surface of NPs, resulting in the formation of cardiac targeting peptide (CTP)-NPs (designated as CTP-NP1, CTP-NP2, and CTP-NP3). To assess their effectiveness, we compared the binding efficiency of these three CTP-NPs to human and mouse cardiomyocytes. Additionally, we determined their distribution 24 h after injecting the CTP-NPs intravenously into adult C57BL/6J mice. Results: When compared to control NPs without CTP (Con-NPs), all three CTP-NPs exhibited significantly increased binding affinity to both human and mouse cardiomyocytes in vitro and enhanced retention in mouse hearts in vivo. A thorough assessment of the heart sections demonstrated that the binding specificity of CTP-NP3 to cardiomyocytes in vivo was significantly greater than that of Con-NPs. None of the three CTP-NPs were proven to cause cardiomyocyte apoptosis. Conclusions: Biocompatible and safe CTP-NP3 can target the heart via binding to cardiomyocytes. This approach of targeting specific molecules-coated NPs may help in delivering therapeutic compounds to cardiomyocytes for the treatment of heart diseases with high efficacy and low toxicity to other tissues.
Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor
Shirsat, Hemlata , Zhou, Fang , Rekhtman, Natasha , Saqi, Anjali , Argyropoulos, Kimon V. , Azour, Lea , Simms, Anthony, Melamed, Jonathan , Hung, Yin P. , Roden, Anja C. , Moreira, André L. , Narula, Navneet , Saqi, Anjali , Argyropoulos, Kimon , Azour, Lea , Hung, Yin P , Chang, Jason C. , Mino-Kenudson, Mari A.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2020 | Volume: 155 | Issue: 6 | Pages: 832-844

10.1093/ajcp/aqaa194 | PMID 33313677 Get It

Abstract Objectives To describe the histologic features that are helpful in the diagnosis of the rare bronchiolar adenomas/ciliated muconodular papillary tumors (BAs/CMPTs) during intraoperative consultation. Methods Multi-institutional retrospective review of frozen sections of 18 BAs/CMPTs. Results In 14 of 18 cases, BA/CMPT was the primary reason for sublobar lung resection, and in 4 cases, BA/CMPT was an incidental finding intraoperatively for resections performed for carcinoma in other lobes. There were 11 proximal-type/classic BAs/CMPTs and 7 distal-type/nonclassic BAs/CMPTs. Only 3 (16.7%) of 18 were correctly diagnosed at the time of frozen section, all of which were proximal type/classic. The remainder were diagnosed as adenocarcinoma (n = 7); invasive mucinous adenocarcinoma (n = 1); non–small cell lung carcinoma (n = 1); cystic mucinous neoplasm, favor adenocarcinoma (either mucinous or colloid type) (n = 1); favor adenocarcinoma, cannot exclude CMPT (n = 1); atypical proliferation (n = 2); mucinous epithelial proliferation (n = 1); and mucous gland adenoma (n = 1). Conclusions BA/CMPT can potentially be misdiagnosed as carcinoma during intraoperative consultation. On retrospective review of the frozen sections, the presence of the following may help to avoid misdiagnosis: a mixture of bland ciliated columnar cells, mucinous cells, and, most important, a basal cell layer, as well as a lack of necrosis, significant atypia, and mitoses.